Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signalling pathway
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgae143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Rui Yu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology, Academy of Military Medical Sciences, 20 Dongdajie Street, Fengtai District, Beijing 100071, China. Hauptthemen laut MEDLINE: Thymosin, Transforming Growth Factor beta1, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Shenzhen Science and Technology Program, The Fundamental Research Funds for the Central Universities, Nankai University.
Abstract (Originalsprache)
Objectives
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fibrotic interstitial lung disease. The two drugs indicated for IPF have limited efficacy and there is an urgent need to develop new drugs. Thymosin β4 (Tβ4) is a natural endogenous repair factor whose antifibrotic effects have been reported. This study aimed to evaluate the effect of exogenous recombinant human thymosin beta 4 (rhTβ4) on pulmonary fibrosis.
Methods
Pulmonary fibrosis was induced in mice with bleomycin, and rhTβ4 was administrated by nebulization following three strategies: early dosing, mid-term dosing, and late dosing. The rhTβ4 efficacy was assessed by hydroxyproline, lung function, and lung histopathology. In vitro, the effects of rhTβ4 on fibroblast and lung epithelial cell phenotypes, as well as the TGF-β1 pathway, were evaluated. Key findings Aerosol administration of rhTβ4 could alleviate bleomycin-induced pulmonary fibrosis in mice at different stages of fibrosis. Studies conducted in vitro suggested that rhTβ4 could suppress lung fibroblasts from proliferating, migrating, and activation via regulating the TGF-β1 signalling pathway. In vitro, rhTβ4 also inhibited the epithelial-mesenchymal transition-like process of pulmonary epithelial cells.
Conclusions
This study suggests that nebulized rhTβ4 is a potential treatment for IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology, Academy of Military Medical Sciences, 20 Dongdajie Street, Fengtai District, Beijing 100071, China.
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China.
ORCID-Profile: Shimeng Li, Li Chen
Förderung
- Shenzhen Science and Technology Program
- The Fundamental Research Funds for the Central Universities
- Nankai University
- The National Natural Science Foundation of China
Zitieren
APA
Yu, R., Li, S., Chen, L., Hu, E., Chai, D., Liu, Z., Zhang, Q., Mao, Y., Zhai, Y., Li, K., Liu, Y., Li, X., Zhou, H., Yang, C., & Xu, J. (2025). Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signalling pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae143
Vancouver
Yu R, Li S, Chen L, Hu E, Chai D, Liu Z, et al. Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signalling pathway. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae143
BibTeX
@article{Yu2025,
author = {Yu, Rui and Li, Shimeng and Chen, Li and Hu, Enbo and Chai, Dan and Liu, Zhichao and Zhang, Qianyi and Mao, Yunyun and Zhai, Yanfang and Li, Kai and Liu, Yanhong and Li, Xiaohe and Zhou, Honggang and Yang, Cheng and Xu, Junjie},
title = {Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signalling pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgae143}
}
EUVIMED